An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. - Wikidata - wikimedia - TriplyDB

An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities.

An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities.

http://www.wikidata.org/entity/Q33274608

about

Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types Insights into cytokine-receptor interactions from cytokine engineering Receptor dimerization dynamics as a regulatory valve for plasticity of type I interferon signaling Structural Linkage between Ligand Discrimination and Receptor Activation by Type I Interferons Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation.Instructive roles for cytokine-receptor binding parameters in determining signaling and functional potency Disease-promoting effects of type I interferons in viral, bacterial, and coinfections Live cell micropatterning reveals the dynamics of signaling complexes at the plasma membrane Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis Multifaceted activities of type I interferon are revealed by a receptor antagonist.Stochastic receptor expression determines cell fate upon interferon treatment.Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma.Production and characterization of thirteen human type-I interferon-α subtypes.Binding of interferon reduces the force of unfolding for interferon receptor 1.IFNB1/interferon-β-induced autophagy in MCF-7 breast cancer cells counteracts its proapoptotic function.Type I interferons in viral control and immune regulation Receptor density is key to the alpha2/beta interferon differential activities.Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma.Bridging the species divide: transgenic mice humanized for type-I interferon response.Spatiotemporal control of interferon-induced JAK/STAT signalling and gene transcription by the retromer complex.Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury.Cytokine-receptor interactions as drug targets.Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy.Multifarious determinants of cytokine receptor signaling specificity.Type I Interferon Signaling Is Decoupled from Specific Receptor Orientation through Lenient Requirements of the Transmembrane Domain.Fine Tuning of a Type 1 Interferon Antagonist.Molecular dissection of the interactions of an antitumor interleukin-2-derived mutein on a phage display-based platform.The molecular basis for differential type I interferon signaling.Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands.NMR mapping of the IFNAR1-EC binding site on IFNalpha2 reveals allosteric changes in the IFNAR2-EC binding site.Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties.The IFN-λ-IFN-λR1-IL-10Rβ Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity.Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection In Vivo.Ligand-induced type II interleukin-4 receptor dimers are sustained by rapid re-association within plasma membrane microcompartments.A panel of synthetic antibodies that selectively recognize and antagonize members of the interferon alpha family.A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon.Anti-obesity and anti-tumor pro-apoptotic peptides are sufficient to cause release of cytochrome c from vesicles.Phagekines: Screening Binding Properties and Biological Activity of Functional Cytokines Displayed on Phages.Dynamic Modulation of Binding Affinity as a Mechanism for Regulating Interferon Signaling.The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities.

P2860

Q21131160-819D0365-7E03-474B-95BF-FFBBC2472451 Q26852703-3BA93F1B-F05D-4175-AF89-C1ECBF42C866 Q27310374-A087F509-FDDB-455E-ACC6-54787B1D4457 Q27671836-E6FC8959-B7D5-44EC-AA1D-17E070C853CE Q27687338-3EEE70AC-4C6B-4CF8-AFA1-43E21BA5E5FB Q27702599-C28494B7-1CA2-4FED-8E5C-F131BFD5F47E Q28082841-1A7A0415-749E-4E24-87F3-AB1CD175E6F4 Q30597262-EAF4B520-1D38-4B78-80E9-C986B4C6F954 Q34355672-14C39E8C-7C9C-43B4-996B-3629A630F217 Q35031568-03BB92CB-A171-4222-BB68-5A2012748D00 Q35139921-570AF7CD-773E-4FD9-9D0F-F64DF0758A12 Q35321868-DFE3C305-595D-4B5F-8116-6D86D6E5E46F Q35740830-7277C14D-F3EF-4A5A-A3C1-C812CAC54C28 Q36344846-ED6FA6DE-563C-4927-AB18-4F2C6F8049E0 Q36662334-E2742C89-BEA0-4023-B13D-67CE5C79D0CF Q36767643-1CFD4C56-1E08-4B5D-83DB-4809BEAD1B99 Q37302247-CE365875-28F5-4EE7-A874-436022A458D4 Q37327294-2B9A6840-393C-41EF-8E5A-59498FBE9E3A Q37458573-A78E4155-02C7-4E6D-A477-F03EF47309EE Q37492886-31B96103-1554-4BE8-B7D5-64CD56C66474 Q37644388-312BF992-FC2B-45B0-9AEC-0D05BA617084 Q37771522-8A7A450C-CAA5-4A6E-B5C4-68A8A60F747A Q38097519-E3A41831-976C-4A65-B736-1E35FBA83CB6 Q38175584-756E3A86-674F-4B1B-8778-4E1184C434B5 Q38378144-5560BBF3-1583-4C60-AEDB-188FD61B672F Q38855055-E1B21DC4-5DBE-4682-B63C-413BE99736C3 Q38909407-EB296C84-4B99-4511-825E-C6EF1991BDA6 Q39176574-9A5E8BF5-8940-45DD-AABF-4CC1FA229017 Q39228077-0B23E237-AFC5-45D3-ABF9-9B62AC35ACE3 Q39246610-483C7CF1-EFAD-4FB1-BCE3-D22D26378022 Q39572512-1D82CCA4-054E-4C32-B6CF-C52BDE6A8AD4 Q40280003-8DBAE575-0D2C-4189-BC07-9AC83D8D575E Q40705563-D57589B9-F795-4AF6-BAFB-EF81CF69129D Q41077405-97FA79D6-7CF1-4D6B-B9F7-01B5ACC146F3 Q41923577-E5FDC985-158E-4C0F-B409-B9E86D5E77B2 Q42293264-9DD341A7-DED6-488E-AC86-72102B71FDF4 Q42918264-A0383FD4-19F5-48CF-B4E2-402DDA897169 Q47425474-BC34412E-CDCF-4B9E-A847-0D54DBD6C481 Q47565835-BBC0BAE1-E6FA-4D3F-B583-BEF1864A98D1 Q54399469-6297C430-6249-482E-9D6A-3896C07F56FA

P2860

An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities.

http://www.wikidata.org/entity/Q33274608

description

2007 nî lūn-bûn

@nan

2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

An interferon alpha2 mutant op ...... enhanced antitumor activities.

@ast

An interferon alpha2 mutant op ...... enhanced antitumor activities.

@en

An interferon alpha2 mutant op ...... enhanced antitumor activities.

@nl

type

label

An interferon alpha2 mutant op ...... enhanced antitumor activities.

@ast

An interferon alpha2 mutant op ...... enhanced antitumor activities.

@en

An interferon alpha2 mutant op ...... enhanced antitumor activities.

@nl

prefLabel

An interferon alpha2 mutant op ...... enhanced antitumor activities.

@ast

An interferon alpha2 mutant op ...... enhanced antitumor activities.

@en

An interferon alpha2 mutant op ...... enhanced antitumor activities.

@nl

P1433

Q33274608-F4E5AD7F-63DB-469F-B703-00F7FC8703DB

P1476

Q33274608-E5590C47-DC61-4801-BAD3-A4C8E950F3D1

P2093

Q33274608-1D243320-A0DF-44CC-9770-08B3B48EC59F

Q33274608-57D68808-4AE5-410A-8F42-CA57E160468C

Q33274608-C4B4E73F-6B65-417C-A822-859901AAE218

Q33274608-F7CE7C02-1AA7-4B39-8646-41F873DD6703

P2860

Q33274608-017A58C8-1A92-4006-8219-B017EA410DFB

Q33274608-026735C8-7FA1-4F52-BF87-80F086776CBC

Q33274608-1D2838B6-40F8-4463-9CAF-50A65552A8AA

Q33274608-1DB34A9B-06B6-4E0F-86A9-61FECDF320D8

Q33274608-1E2B2615-55FB-4008-AE7A-14124B0C7DA4

Q33274608-1F8D33A3-ECF1-412B-893C-F3213B3F5E77

Q33274608-2457B29B-658F-4D4D-9419-9D69E0B1070C

Q33274608-2592BF49-B672-4992-A8FD-2CC77129A04F

Q33274608-392D46A1-3BC9-4886-B200-BA86E77069EB

Q33274608-3ADAA2DD-1E3A-47B8-91B4-4E6B0F06EF59

P304

Q33274608-A386960A-E44F-4372-BCC7-8E073203FF87

P31

Q33274608-C2108983-D30A-45EC-A6F1-551C7C010412

P356

Q33274608-9F9DF814-DB34-4801-A29C-9FA219994528

P407

Q33274608-F74A3E3F-7DC4-4B7B-BBF7-D48377F79A83

P433

Q33274608-1797379C-7AC1-44B1-9DF0-661BF1409655

P478

Q33274608-DFD95813-2088-4618-810F-08A92F97C3A3

P577

Q33274608-88DFB97D-23F4-45B1-BFB7-568E9B165764

P698

Q33274608-1119DC0B-7BA4-4D8A-9AA6-2057B1098839

P921

Q33274608-CB622CAE-9D10-4BA2-85EA-C8A808D51AF2

P356

P1433

Journal of Biological Chemistry

P1476

An interferon alpha2 mutant op ...... enhanced antitumor activities.

@en

P2093

Diego A Jaitin

http://www.w3.org/2001/XMLSchema#string

Eyal Kalie

http://www.w3.org/2001/XMLSchema#string

Gideon Schreiber

http://www.w3.org/2001/XMLSchema#string

Renne Abramovich

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA

Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest

The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution

How cells respond to interferons

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

Mechanisms of type-I- and type-II-interferon-mediated signalling

Catalytically active TYK2 is essential for interferon-beta-mediated phosphorylation of STAT3 and interferon-alpha receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase

Phage display for selection of novel binding peptides.

Fast transient cytokine-receptor interactions monitored in real time by reflectometric interference spectroscopy.

Biophysical analysis of the interaction of human ifnar2 expressed in E. coli with IFNalpha2.

P304

11602-11611

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M610115200

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

282

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17310065

http://www.w3.org/2001/XMLSchema#string

P921